Research Progress Of Neuroprotective Effect Of Uric Acid On Parkinson Disease

Parkinson’s disease (PD) is a movement disorder of central neivoussystem commonly seen in middle-aged and elderly people. It is pathologicallyfeatured by progressive losses of dopaminergic neurons in thenigrostriatal system and the formation of Lewy body in substantia nigra.It is manifested by motor symptoms like resting tremor, rigidity, slowness ofmovement and non-motor symptoms, such as cognitive decline, depression,sleep disorders, olfactory dysfunction, constipation. Under the interactedinfluence of genetic and environmental factors, mounting dopamine neuronsbecame degeneration and death throughing oxidative stress, mitochondrialdysfunction, misfolding or abnormal aggregation and degradation of proteins,immunizing inflammatory reaction and excitatory neurotoxicity. Uric acid(UA) is the end product of adenosine, guanosine or ribonucleic acid in the dietthroughing purine metabolism. UA is the Physiological antioxidant substancesin the human body. Epidemiological and clinical studies suggested that UAlevel was closely related to the incidence of PD. UA level was significantlydecreased in patients with PD and a relatively higher level of UA in blood andcerebrospinal fluid could slow down the progress of PD. UA was also related tothe occurrence of nor-motor symptoms and wearing-off phenomenons in patientswith PD. Studies have shown UA has protective effect on dopamine neurons.Regulating UA level may become a new target for the prevention of PD.